Genmab A/S
GMABNasdaqPharmaceutical PreparationsAlso trades as GNMSF
Financials through fiscal 2025, year ended Dec 31, 2025Score 0/30
$50.97−0.99 (-1.91%)
Close on Nov 18, 2026
Genmab A/S Receivables Related to Collaboration Agreements by Quarter
Receivables Related to Collaboration Agreements ($M)
Genmab A/S Receivables Related to Collaboration Agreements: $992M in Q3 2026.
Latest, Q3 2026
992
Period ended Sep 30, 2026
Change on a year earlier
–
History
4 quarters
Since Q4 2025
Sources
4
Documents cited below
Where the Q3 2026 figure comes from
“|| Receivables related to collaboration agreements | $ | 992 | $ | 907”
Source: Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗
quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Receivables Related to Collaboration Agreements ($M) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 992 | – | Genmab Form 6-K — Q3 2026 Interim Report (Nine Months Ended Sep 30, 2026) ↗ |
| Q2 2026 | Jun 30, 2026 | 969 | – | Genmab Form 6-K — H1 / Q2 2026 Interim Report (Six Months Ended Jun 30, 2026) ↗ |
| Q1 2026 | Mar 31, 2026 | 755 | – | Genmab Form 6-K — Q1 2026 Interim Report (Three Months Ended Mar 31, 2026) ↗ |
| Q4 2025 | Dec 31, 2025 | 907 | – | Genmab Statutory Annual Report 2025 (Consolidated, ESRS & Parent Company FS, Form 20-F Ex.) ↗ |
Cite this data
StockData. (2026). Genmab A/S Receivables Related to Collaboration Agreements ($M), quarterly Q4 2025–Q3 2026 [Data set]. Compiled from Genmab A/S SEC filings and investor materials. https://stockdatahq.com/stocks/gmab/kpis/collab-receivables
See every metric in the Genmab A/S KPI table. Data updated Nov 11, 2026.
See a number that looks wrong?